Adipocyte

Celluma Light Therapy Announces Launch of Revolutionary Body Contouring Device

Retrieved on: 
Friday, March 1, 2024

TUSTIN, Calif., March 1, 2024 /PRNewswire/ -- BioPhotas, Inc., the market leader in therapeutic LED Light Therapy Devices, announced today the launch of the Celluma CONTOUR, the only FDA-cleared light therapy device treating body contouring, aging skin, and pain management.

Key Points: 
  • TUSTIN, Calif., March 1, 2024 /PRNewswire/ -- BioPhotas, Inc., the market leader in therapeutic LED Light Therapy Devices, announced today the launch of the Celluma CONTOUR, the only FDA-cleared light therapy device treating body contouring, aging skin, and pain management.
  • "The Celluma CONTOUR is the first LED Light Therapy device to be FDA-cleared on an Over-The-Counter basis for body contouring," commented BioPhotas President and CEO, Curtis Cluff.
  • "It is also the only LED light therapy device on the market designed with multiple treatment modes for reducing wrinkles, reducing muscle and joint pain, as well as body contouring in a single device."
  • Low Level Light Therapy (LLLT) for body contouring is a proven, non-invasive technique to reduce the circumference of the hips, waist, and thighs safely and effectively.

Kriya Announces Gene Therapy Program for Thyroid Eye Disease

Retrieved on: 
Friday, January 5, 2024

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., (Kriya) a biopharmaceutical company developing gene therapies for common diseases affecting millions of people around the world, today announced its gene therapy program for thyroid eye disease (TED), a debilitating autoimmune condition resulting in proptosis and diplopia, medical terms describing bulging of the eyes and double vision respectively, due to inflammation of the muscles and fat tissue behind the eye. TED affects approximately one million people in the United States and the European Union.

Key Points: 
  • TED affects approximately one million people in the United States and the European Union.
  • Kriya is developing KRIYA-586, a one-time, adeno-associated virus (AAV) gene therapy that drives durable expression of a monoclonal antibody that blocks IGF-1 receptors.
  • IGF-1R blockade has been established as a clinically validated mechanism of action, as evidenced by teprotumumab, the first and only FDA-approved therapy for TED.
  • "We believe that an in-office, focally administered gene therapy for TED would meaningfully improve the quality of life of people with TED, with the potential to durably address the disease following one-time injection,” said Shankar Ramaswamy, M.D., Co-Founder and CEO of Kriya.

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

Retrieved on: 
Tuesday, December 12, 2023

MELVILLE, N.Y., Dec. 12, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program. The notice of allowance was issued on October 26, 2023. The application is scheduled to issue as U.S. Patent No. 11,851,682 on December 26, 2023.

Key Points: 
  • --Notice of allowance will be the fourth U.S. patent granted under Company’s ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes--
    MELVILLE, N.Y., Dec. 12, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc .
  • (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program.
  • The notice of allowance was issued on October 26, 2023.
  • This notice of allowance will afford us the protections necessary to allocate resources to develop these extremely valuable tools.”

The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Retrieved on: 
Wednesday, December 20, 2023

(NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today reported new data on Namodenoson’s anti-obesity mechanism of action.

Key Points: 
  • (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today reported new data on Namodenoson’s anti-obesity mechanism of action.
  • New data demonstrate that treatment of fat cells (3T3-L1 adipocytes) with Namodenoson leads to modulation of proteins that increase adiponectin level.
  • Adiponectin is a regulator of fat production in the cells, resulting in the inhibition of fat levels.
  • The global obesity treatment market is lucrative due to the awareness of a link between chronic diseases and obesity.

Obatala Sciences Announces Commercial Launch of Its ObaCell® Obesity-on-a-Chip Service

Retrieved on: 
Tuesday, November 28, 2023

Obatala Sciences, a biotechnology company that manufactures stem cells and human-derived hydrogels, announced the accomplishment of a major milestone with the commercial launch of its ObaCell® Obesity-on-a-Chip Service.

Key Points: 
  • Obatala Sciences, a biotechnology company that manufactures stem cells and human-derived hydrogels, announced the accomplishment of a major milestone with the commercial launch of its ObaCell® Obesity-on-a-Chip Service.
  • The new service reflects the commercial development of a family of patents that Obatala licensed from Harvard University in 2021.
  • Obatala Sciences is the first to market a technology that enables a more holistic understanding of human adipose tissue, which is an essential organ that impacts a wide array of metabolic diseases, including obesity and diabetes.
  • Obatala Sciences’ new service offering can reproduce the physiology of obese patients in a lab in ways never possible before, by overcoming size limitations for culturing mature adipocytes in a dish and simulating fasting and feeding in a human model system.

Blocking Abnormal Stem Cell Signal during Aging Lessens Related Bone Loss

Retrieved on: 
Wednesday, September 27, 2023

The study, led by researchers from NYU Grossman School of Medicine, found that blocking the signaling pathway, called Notch, in aging skeletal stem cells caused a "massive increase" in bone mass and restored lost bone-healing ability during aging.

Key Points: 
  • The study, led by researchers from NYU Grossman School of Medicine, found that blocking the signaling pathway, called Notch, in aging skeletal stem cells caused a "massive increase" in bone mass and restored lost bone-healing ability during aging.
  • The study results revolve around immature stem cells, which have the capacity to mature into more than one cell type.
  • Aging is known to come with loss of the ability of stem cells to become bone-making cells, with related skeletal deterioration among the most common causes of age-associated impairment.
  • "Our newly gained knowledge opens potential therapeutic avenues to overcome age-related bone loss by manipulating down-stream effectors for Notch signaling in these stem cells."

Mount Sinai Researchers Uncover How Mammary Glands Control Overall Energy Balance and Fat Metabolism

Retrieved on: 
Wednesday, July 26, 2023

NEW YORK, July 26, 2023 /PRNewswire-PRWeb/ -- An Icahn School of Medicine at Mount Sinai study sheds light on the intricate interplay between mammary adipose (fat) tissue and breast health, and offers exciting possibilities for understanding breast development, lactation, cancer, and obesity and related metabolic disorders.

Key Points: 
  • The researchers discovered a new family of locally secreted and locally acting molecules in the breast called "mammokines" that contribute not only to normal mammary biology, but to overall fat cell physiology and energy balance control.
  • Mammary adipocytes play important roles in organizing mammary ducts, and the reverse is true as well.
  • The new studies reveal an unexpected role for nerve-activated ductal cells in mammary adipocyte metabolism and heat generation.
  • These mammary duct-secreted mammokines play an important role in controlling mammary gland fat abundance and could potentially orchestrate critical processes involved in breast development, lactation, and overall whole-body metabolic regulation.

Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

Retrieved on: 
Monday, April 17, 2023

EDP-235 is currently being evaluated in SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a Phase 2 study of non-hospitalized, symptomatic adults with mild or moderate COVID-19.

Key Points: 
  • EDP-235 is currently being evaluated in SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a Phase 2 study of non-hospitalized, symptomatic adults with mild or moderate COVID-19.
  • Enanta continues to expect topline data from the study in May 2023.
  • EDP-323 is currently being evaluated in a Phase 1 double-blind, placebo-controlled, first-in-human study with a topline data readout planned for the second quarter of 2023.
  • These preclinical data support the potential of EDP-323 as a convenient, once-daily oral treatment for RSV.

Global Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) Strategic Research Report 2023: Activities of 110+ Leading MSC Companies, Including their Core Technologies and Products - ResearchAndMarkets.com

Retrieved on: 
Friday, April 7, 2023

The "Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) - Advances & Applications, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) - Advances & Applications, 2023" report has been added to ResearchAndMarkets.com's offering.
  • MSCs are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes.
  • Therefore, this global strategic report details the activities of 113 leading MSC companies, including their core technologies and products under development.
  • This global strategic report includes:
    Market size determination for the global MSC market, segmented by Geography and Business Segment
    Recent business developments related to MSCs, including strategic collaborations and partnerships
    Company profiles for MSC market competitors, including their products, services, and technologies under development

Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research

Retrieved on: 
Tuesday, March 14, 2023

Additional preclinical data show EDP-235’s targeted tissue penetration and potential to mitigate rebound in COVID-19 patients.

Key Points: 
  • Additional preclinical data show EDP-235’s targeted tissue penetration and potential to mitigate rebound in COVID-19 patients.
  • Additional preclinical data demonstrate that EDP-235’s optimized tissue targeting may help to minimize viral rebound.
  • To evaluate the impact of EDP-235 treatment on SARS-CoV-2 transmission, infected source animals were co-housed with uninfected contact animals 60 hours post-infection.
  • This high throughput screen identified multiple, structurally diverse, non-nucleoside SARS-CoV-2 RdRp inhibitors as potential starting points for hit optimization.